Zai Lab (09688) rose more than 4% in Hong Kong trading, with the stock up 4.22% to HK$15.79 by the time of writing, as turnover reached HK$98.01 million. The increase follows an announcement on April 1 that Zai Lab has entered into a global clinical research collaboration with Amgen. The partnership aims to evaluate Zai Lab’s clinical-stage antibody-drug conjugate (ADC) zocilurtatug pelitecan (zoci, formerly known as ZL-1310), which targets delta-like ligand 3 (DLL3), in combination with Amgen’s IMDELLTRA® (tarlatamab), a bispecific T-cell engager (BiTE®) therapy also targeting DLL3, for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Under the agreement, Amgen will sponsor a global Phase 1b study to assess the safety and efficacy of zoci combined with IMDELLTRA® in ES-SCLC patients. Zai Lab will retain full ownership of zoci and will supply the investigational drug for the clinical study.